Target intelligence / Profile preview

Proteasome subunit beta type-8 (PSMB8)

Target
PSMB8
Molecular classification
Enzyme, Protease, Threonine protease
01

Overview

The 20S immunoproteasome beta-5i chymotrypsin-like site is the primary catalytic center of the Proteasome subunit beta type-8 (PSMB8), also known as LMP7. This subunit is an inducible component of the immunoproteasome, a specialized variant of the 20S proteasome core particle that is constitutively expressed in hematopoietic cells and upregulated in other tissues by pro-inflammatory cytokines such as interferon-gamma. The beta-5i site possesses chymotrypsin-like activity, which is responsible for cleaving peptide bonds after hydrophobic amino acid residues. This specific proteolytic profile is crucial for generating peptides with high affinity for MHC class I molecules, thereby facilitating the presentation of antigens to CD8+ T cells and driving adaptive immune responses. Pharmacological inhibition of this site is a therapeutic strategy for treating autoimmune and inflammatory diseases, such as systemic lupus erythematosus and rheumatoid arthritis, as well as hematological malignancies like multiple myeloma. Selective inhibitors, such as zetomipzomib (KZR-616) and ONX-0914, are designed to target the immunoproteasome while sparing the constitutive proteasome to reduce systemic toxicities like peripheral neuropathy. However, challenges remain regarding the potential for excessive immunosuppression and the risk of triggering autoinflammatory responses in susceptible individuals.

Other names
LMP7RING10Beta5iPSMB5iD6S216D6S216EJMPNKJOALDDPRAAS1Proteasome 20S subunit beta 8
02

Mechanism of action

Inhibition of the chymotrypsin-like catalytic activity of the immunoproteasome beta-5i subunit

03

Biological functions

Immune responseAntigen processingProtein degradationApoptosisOxidative stress defenseNF-kappaB activation
04

Disease associations

InflammationAutoimmune diseaseCancerNeurodegenerative diseaseCANDLE syndrome
05

Safety considerations

ImmunosuppressionOff-target inhibition of constitutive proteasomePeripheral neuropathyHematological toxicityAutoinflammatory reactions
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

PSMB8 expressionMHC class I expressionInterleukin-6 levelsTumor necrosis factor-alpha levels

Beyond the preview

Go deeper on Proteasome subunit beta type-8 (PSMB8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome subunit beta type-8 (PSMB8).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call